The best Christmas gift?
A future free from blood cancer

Every 27 minutes, someone like Dom is diagnosed with blood cancer. The clock is ticking. 

Dom Scoleri, blood cancer patient
  • attach_money
  • person
  • credit_card

Give to vital cancer research
this Christmas

I'd like to donate

$75
Can help fund one hour of life-saving cancer research
$125
Can help pay for microscopy to look for immune cells in tumours
$550
Can help fund omics analysis software to study molecular profiles
$1,000
Can help provide cutting-edge software to analyse cells and help find a cure
$

All payments are secured and encrypted.

Your Details

All payments are secured and encrypted.

Payment Details

$0.00

All payments are secured and encrypted.

  • Len just donated $670
  • barry just donated $84.40
  • Callan just donated $5.28
  • Kathleen just donated $158.25
  • Jeremy just donated $79.13
  • Sandy just donated $52.75
  • Beverley just donated $158.25
  • Gitanjali just donated $263.75
  • Margaret just donated $105.50
  • Hylin just donated $16.80
  • Heidi and David just donated $105.50
  • Len just donated $26.38
  • Anonymous just donated $105.50
  • Vivian just donated $21.10
  • Jan just donated $1,020
  • george just donated $1.06
  • Peter just donated $263.75
  • Alexandra just donated $73.85
  • Tecia just donated $10
  • Robert just donated $200

Blood cancer in Australia

Blood cancer in Australia

"If it wasn’t for cancer research, I wouldn't be here today": Dom’s blood cancer story

Dom Scoleri with his mum

Dom celebrating his mum’s 80th birthday.

My family started preparing for my funeral when I told them I had cancer.”

Dom had been unwell for a long time. After months of going to the doctor for debilitating fatigue and bone pain, he finally had an answer: multiple myeloma, an incurable and often aggressive form of blood cancer.  

Each day in Australia, six more people like Dom receive this life-altering news, their worlds forever changed as they face an uncertain future and the reality of lifelong treatment. 

Like many others, he was given just five years to live – if he were lucky. But after a successful stem cell transplant, clinical trial and countless therapies, he’s still here 10 years later, celebrating another Christmas with his loved ones.  

Thanks to generous supporters like you that have empowered advancements in cancer research, myeloma is no longer a death sentence. But patients still endure ongoing treatments that take a heavy toll, and sadly, the disease often cuts lives short, making every moment even more precious.  

"I know I have an incurable disease. Sooner or later, my time will come, but I try and live for today as much as I can.” 

This Christmas, your generosity can change the future for someone like Dom. There's no cure for cancers like multiple myeloma – yet. With your help, we're one step closer. 

You can bring us closer to life-changing breakthroughs in blood cancer and beyond

“I am incredibly grateful for the research funding we receive; it is vital to support our efforts to explore and decode the complexities of myeloma with our ultimate goal to improve outcomes for those living with the disease.”

Dr Melissa Cantley, a blood cancer researcher funded by Cure Cancer, started her groundbreaking work identifying blood biomarkers in patients with high-risk smouldering myeloma (an early form of myeloma with no symptoms) thanks to early support from the organisation that was made possible by people like you.

Her research focuses on detecting early signs of cancer progression that helps doctors to act sooner and stop the cancer before it fully develops. She is now working with a team that has initiated a national study aimed at identifying blood-based biomarkers, working with experts across Australia to advance this important research.

Investing in cancer research like hers brings us closer to breakthroughs that give cancer patients more hope, more time, and better lives.  

Dr. Melissa Cantley, Blood cancer researcher

Dr Melissa Cantley, Cure Cancer-funded blood cancer researcher

How your donation helps

$75

Can help fund an hour of research

$125

Can help fund microscopy imaging to look for immune cells in tumours

$550

Can help provide lab supplies for up to 10 vital experiments

$1,000

Can help provide cutting-edge software to analyse cells

Our blood cancer stories

Dom Scoleri with his dog

Dom's story: Multiple myeloma

Buzz's story: Acute lymphoblastic leukaemia

Sarah's story: A rare leukaemia

Our blood cancer researchers

Frequently Asked Questions

What is blood cancer?

add remove

Blood cancer occurs when normal blood cell production, which happens in the bone marrow, is interrupted by the uncontrolled growth of an abnormal type of blood cell. When abnormal blood cells build up in the blood, it can affect how the rest of the body functions. 

Blood cancer is the second most common cancer diagnosis and also the second most common cause of cancer-related deaths in Australia in the latest national report. Although incidence for most cancer types have largely improved over the years, blood cancer remains an exception. Incidence of this type of cancer continues to grow, and it is up to 47% in the last 10 years alone.

What are the types of blood cancer?

add remove

Blood cancers are categorised according to the type of cells affected. There are three main types:

Leukaemia

Leukaemia starts in the bone marrow where developing blood cells (usually white cells) undergo a malignant change. These cells then crowd the marrow, affecting the body’s ability to produce normal blood cells. There are four kinds of leukaemia: acute lymphoblastic, acute myeloid, chronic lymphocytic, and chronic myeloid. In 2021, an estimated 2,029 deaths in Australia were due to leukaemia. The five-year survival rate has significantly improved in the last twenty years, from 43% in 1988-1992 to 63% in 2013-2017.

Symptoms can include:

  • Signs of anaemia

  • Chronic infection (such as fevers, sweats, sores)

  • Enlarged lymph nodes

  • Joint pain

  • Spontaneous bruising and increased bleeding
  • Painful passing of urine



Lymphoma

Lymphomas affect the lymphatic system, part of the immune system which protects the body against disease and infection. These occur when lymphocytes (a type of white blood cell) undergo a malignant change and multiply in an uncontrolled way. The lymphoma cells then accumulate to form tumours in the lymph nodes, which are located throughout the body. There are two types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma, which can be distinguished by the specific lymphocytes involved.

Symptoms can include:

  • Swelling of lymph nodes

  • Fever

  • Night sweats

  • Sudden weight loss
  • Fatigue
  • Shortness of breath



Myeloma

Myeloma develops in plasma cells (a type of white cell) of the bone marrow. It is often called multiple myeloma because marrow is found in multiple bones such as the spine, skull, ribs, pelvis, and shoulder. The five-year survival rate for myeloma is 51%.

Symptoms can include:

  • Kidney problems

  • Frequent nose bleeding

  • Feeling pain in the bones

  • Fatigue

  • Chronic infections that don’t go away

What are the risks associated with blood cancer?

add remove

Exposure to radiation and certain chemicals or solvents is a known risk associated with leukaemia, lymphoma, and myeloma. HIV infection, which can weaken the immune system, Epstein-Barr virus (herpesvirus 4), and Human T-Cell leukaemia virus, can also increase risk.

People assigned male at birth are at a slightly greater risk of lymphoma. Having a family history of Hodgkin lymphoma increases the risk of this disease, and it is also more common in early adulthood (people in their 20s). Non-Hodgkin lymphoma is more common in late adulthood (60 above). 

Thank you to our supporters

Adam Dziurhaluk

i hope this small donation can help.40

$132

Anonymous

$11

Belinda Charles

She is a survivor. She is a warrior. She is what she is meant to be to the world.

$136

Anonymous

$5

Together, we can cure cancer.

Let's stay in touch

To receive updates on our work, campaigns and our impact in cancer research, subscribe to our newsletter.